Cyclo Therapeutics (NASDAQ:CYTH – Get Free Report) and Curis (NASDAQ:CRIS – Get Free Report) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, valuation, dividends, analyst recommendations, institutional ownership and profitability.
Insider and Institutional Ownership
68.6% of Cyclo Therapeutics shares are owned by institutional investors. Comparatively, 30.0% of Curis shares are owned by institutional investors. 29.8% of Cyclo Therapeutics shares are owned by insiders. Comparatively, 5.7% of Curis shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Risk and Volatility
Cyclo Therapeutics has a beta of -0.46, suggesting that its stock price is 146% less volatile than the S&P 500. Comparatively, Curis has a beta of 3.35, suggesting that its stock price is 235% more volatile than the S&P 500.
Valuation and Earnings
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Cyclo Therapeutics | $870,725.00 | 19.66 | -$20.06 million | ($0.90) | -0.66 |
| Curis | $10.26 million | 2.62 | -$47.41 million | ($7.81) | -0.41 |
Cyclo Therapeutics has higher earnings, but lower revenue than Curis. Cyclo Therapeutics is trading at a lower price-to-earnings ratio than Curis, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Cyclo Therapeutics and Curis’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Cyclo Therapeutics | -2,847.19% | -2,741.89% | -307.16% |
| Curis | -443.35% | -923.37% | -78.35% |
Analyst Ratings
This is a breakdown of current ratings and recommmendations for Cyclo Therapeutics and Curis, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Cyclo Therapeutics | 0 | 2 | 1 | 0 | 2.33 |
| Curis | 0 | 0 | 3 | 0 | 3.00 |
Cyclo Therapeutics currently has a consensus price target of $0.95, suggesting a potential upside of 59.61%. Curis has a consensus price target of $23.00, suggesting a potential upside of 625.55%. Given Curis’ stronger consensus rating and higher probable upside, analysts clearly believe Curis is more favorable than Cyclo Therapeutics.
Summary
Curis beats Cyclo Therapeutics on 9 of the 14 factors compared between the two stocks.
About Cyclo Therapeutics
Cyclo Therapeutics, Inc., a clinical stage biotechnology company, engages in the development of cyclodextrin-based products for the treatment of neurodegenerative diseases. The company's lead drug candidate is Trappsol Cyclo (hydroxypropyl beta cyclodextrin), an orphan drug, which is in Phase III clinical trials for the treatment of Niemann-Pick Type C disease; and in Phase IIb clinical trials for the treatment of Alzheimer's disease. It also sells cyclodextrins and related products to the pharmaceutical, nutritional, and other industries, primarily for use in diagnostics and specialty drugs. The company was formerly known as CTD Holdings, Inc. and changed its name to Cyclo Therapeutics, Inc. in September 2019. Cyclo Therapeutics, Inc. was incorporated in 1990 and is headquartered in Gainesville, Florida.
About Curis
Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small molecule IRAK4 kinase inhibitor, which is in a Phase 1/2 open-label, single arm expansion trial in patients with relapsed or refractory, or R/R, AML and high-risk myelodysplastic syndromes. The company’s pipeline also includes Fimepinostat, an oral dual inhibitor of HDAC and PI3K enzymes for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma; CA-170, an oral, small molecule antagonist designated as CA-170 that selectively targets PD-L1 and VISTA; and CA-327, an oral, small molecule, TIM3/PD-L1, which is a molecule antagonist of PD-L1 and TIM3. It has collaboration agreement with Genentech Inc., or Genentech and F. Hoffmann-La Roche Ltd, or Roche, for the commercialization of Erivedge, an orally-administered small molecule hedgehog signaling pathway antagonist for the treatment of advanced basal cell carcinoma, or BCC; Aurigene Discovery Technologies Limited for the discovery, development, and commercialization of small molecule compounds in the areas of immuno-oncology and precision oncology; and also licensed four programs under the Aurigene collaboration, including emavusertib. Curis, Inc. was incorporated in 2000 and is headquartered in Lexington, Massachusetts.
Receive News & Ratings for Cyclo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cyclo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
